Analsts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and C.R. Bard (NYSE: BCR)

By George MacDonald

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (NYSE: ABT) and C.R. Bard (NYSE: BCR).

Abbott Laboratories (NYSE: ABT)

Deutsche Bank analyst Kristen Stewart maintained a Buy rating on Abbott Labs (NYSE: ABT) on January 29. The company’s shares closed last Friday at $37.85, close to its 52-week low of $36.

Currently, the analyst consensus on Abbott Labs is Moderate Buy and the average price target is $49, representing a 29.5% upside. In a report issued on January 14, Jefferies also maintained a Buy rating on the stock with a $50 price target.

According to TipRanks.com, Stewart is a 4-star analyst with an average return of 3.1% and a 58.8% success rate. Stewart covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Zimmer Biomet Holdings, and Baxter International.

C.R. Bard (NYSE: BCR)

In a report issued on January 29, Kristen Stewart from Deutsche Bank maintained a Hold rating on C.R. Bard (NYSE: BCR), with a price target of $196. The company’s shares closed last Friday at $183.27.

C.R. Bard has an analyst consensus of Moderate Buy, with a price target consensus of $208.

According to TipRanks.com, Stewart is a 4-star analyst with an average return of 3.1% and a 58.8% success rate. Stewart covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Zimmer Biomet Holdings, and Baxter International.